Assessment of a second-generation bifocal lens


According to Prof. Shah, the second generation Lentis multifocal lens is a significant improvement over its predecessor. In this article, we highlight his study assessing visual outcomes after implantation with this new lens.

Prof. Shah and colleagues assessed visual outcomes after implantation with a new lens, MPlusX (Oculentis, Berlin, Germany), and compared it to previous data obtained with the first generation lens, MPlus, from the same company. "People will be familiar with the MPlus lens, it's the first asymmetric technology and it has become very popular," he continued. "However, it has been available for 4 years now and the challenge then becomes how do you improve it?"

A little extra

The second-generation lens design features a wider multifocal segment and increased asphericity, which Prof. Shah noted implies that there will be some extra near vision achievable.

"We looked at 20 subjects, all of cataract age, who had bilateral implantation and as per standard protocol for us, were examined at 3 months," he explained. Data collected at follow up included uncorrected and corrected distance and near vision, subjective refraction, defocus curve testing, contrast sensitivity, halometry glare testing and a questionnaire to assess near vision function and patient satisfaction.

Significant improvement

"Similar to many lenses, we achieved good unaided distance vision, best-corrected distance vision was also excellent," added Prof. Shah. Additionally, patient satisfaction was recorded as high and they demonstrated good spectacle independence.

"So, across the board with our results, we found that there was a significant improvement in the intermediate and also in the near," he summarized. "We achieved about 1 line better for near, significantly better in intermediate vision and I do feel that this is a significant improvement over the MPlus."


1. S. Shah, 'To assess outcomes of the second generation segmented bifocal lens from Oculentis', Free Paper Presentation, ESCRS 2013, Amsterdam, The Netherlands.

Related Videos
J. Morgan Micheletti, MD, speaks at the 2024 ASCRS meeting
Dr William Wiley of Cleveland Eye Clinic, Northeast Ohio
Filomena Ribeiro, MD, PhD, FEBO, speaks at the 2024 ASCRS meeting
A screenshot of Dr Filomena Ribeiro, president of the ESCRS
© 2024 MJH Life Sciences

All rights reserved.